The prevalence of CLDN18-positive cases is relatively lower in our study in comparison to the recent published clinical trial42 or a previous paper by Matsusaka and colleagues;28 however, our series considered only a 8.6% of stage IV tumours and this can significantly affect the prevalence of CLDN18-positive cases. This evidence concerns the gene CLDN18 and neoplasm.